Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 8.12B | 7.01B | 7.63B | 8.67B | 8.53B |
Gross Profit | 3.92B | 3.37B | 4.03B | 4.60B | 4.23B |
EBITDA | 748.35M | 1.22B | 1.20B | 1.75B | -2.62B |
Net Income | -209.22M | 804.88M | 608.19M | 1.85B | -4.50B |
Balance Sheet | |||||
Total Assets | 22.95B | 23.19B | 22.73B | 23.30B | 21.32B |
Cash, Cash Equivalents and Short-Term Investments | 7.62B | 6.28B | 7.51B | 7.21B | 6.26B |
Total Debt | 166.21M | 238.10M | 617.98M | 1.45B | 1.33B |
Total Liabilities | 4.57B | 4.16B | 4.78B | 6.11B | 6.22B |
Stockholders Equity | 18.37B | 19.02B | 17.96B | 17.19B | 15.09B |
Cash Flow | |||||
Free Cash Flow | 2.41B | 954.13M | 1.25B | 879.35M | 821.95M |
Operating Cash Flow | 2.53B | 1.13B | 1.58B | 1.12B | 1.11B |
Investing Cash Flow | -1.76B | -3.39B | 528.10M | 936.23M | -4.19B |
Financing Cash Flow | -346.01M | -510.82M | -1.15B | -349.99M | -92.34M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $40.59B | 45.82 | 17.66% | 2.48% | 21.71% | 103.69% | |
72 Outperform | HK$18.81B | 7.30 | 10.79% | 8.36% | 0.43% | 21.65% | |
68 Neutral | €25.63B | 14.72 | 6.58% | 8.61% | -6.14% | -15.39% | |
66 Neutral | $29.71B | 27.55 | -1.14% | ― | 13.74% | -125.64% | |
64 Neutral | HK$8.20B | 41.37 | 2.01% | 4.49% | -15.71% | -80.38% | |
61 Neutral | $40.40B | -0.91 | -12.15% | 3.89% | 2.03% | -69.70% | |
58 Neutral | HK$3.06B | ― | -0.40% | ― | -19.99% | 98.97% |
China Literature Limited has announced a board meeting scheduled for August 12, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend, reflecting the company’s ongoing financial strategies and potential shareholder returns.
The most recent analyst rating on (HK:0772) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on China Literature stock, see the HK:0772 Stock Forecast page.
China Literature Limited has announced a significant acquisition, where its PRC operating entity, Shanghai Hongwen, has agreed to acquire a 26.67% equity interest in a target company for approximately RMB324.80 million. This acquisition will increase China Literature’s stake in the target company to 31.48%, although the target will not become a subsidiary, and its financials will remain separate. This transaction is classified as a connected transaction under Hong Kong’s Listing Rules due to Tencent’s involvement, a major shareholder in both China Literature and the target company.
The most recent analyst rating on (HK:0772) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on China Literature stock, see the HK:0772 Stock Forecast page.
China Literature Limited held its Annual General Meeting (AGM) on May 30, 2025, where all proposed resolutions were passed by poll. The resolutions included the re-election of directors, authorization of director remuneration, re-appointment of auditors, and granting of mandates to the directors for share issuance and buyback. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued operational stability and strategic growth.
The most recent analyst rating on (HK:0772) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on China Literature stock, see the HK:0772 Stock Forecast page.
China Literature Limited has announced its upcoming annual general meeting scheduled for May 30, 2025, in Hong Kong. Key agenda items include the consideration of audited financial statements, re-election of directors, and re-appointment of auditors. The meeting will also address resolutions related to the issuance of additional shares and related securities, reflecting the company’s strategic focus on expanding its financial and operational capabilities. This announcement underscores the company’s commitment to maintaining robust corporate governance and enhancing shareholder value.